Top

Published in:

Open Access 01-12-2024 | Insulins | Research

Joint association of TyG index and high sensitivity C-reactive protein with cardiovascular disease: a national cohort study

Authors: Cancan Cui, Lin Liu, Yitian Qi, Ning Han, Haikun Xu, Zhijia Wang, Xinyun Shang, Tianjiao Han, Yining Zha, Xin Wei, Zhiyuan Wu

Published in: Cardiovascular Diabetology | Issue 1/2024

Abstract

Background

Both the triglyceride-glucose (TyG) index, as a surrogate marker of insulin resistance, and systemic inflammation are predictors of cardiovascular diseases; however, little is known about the coexposures and relative contributions of TyG index and inflammation to cardiovascular diseases. Using the nationally representative data from the China Health and Retirement Longitudinal Study (CHARLS), we conducted longitudinal analyses to evaluate the joint and mutual associations of the TyG index and high-sensitivity C-reactive protein (hsCRP) with cardiovascular events in middle-aged and older Chinese population.

Methods

This study comprised 8 658 participants aged at least 45 years from the CHARLS 2011 who are free of cardiovascular diseases at baseline. The TyG index was calculated as Ln [fasting triglyceride (mg/dL) × fasting glucose (mg/dL)/2]. Cardiovascular events were defined as the presence of physician-diagnosed heart disease and/or stroke followed until 2018.We performed adjusted Cox proportional hazards regression and mediation analyses.

Results

The mean age of the participants was 58.6 ± 9.0 years, and 3988 (46.1%) were females. During a maximum follow-up of 7.0 years, 2606 (30.1%) people developed cardiovascular diseases, including 2012 (23.2%) cases of heart diseases and 848 (9.8%) cases of stroke. Compared with people with a lower TyG index (< 8.6 [median level]) and hsCRP < 1 mg/L, those concurrently with a higher TyG and hsCRP had the highest risk of overall cardiovascular disease (adjusted hazard ratio [aHR], 1.300; 95% CI 1.155–1.462), coronary heart disease (aHR, 1.294; 95% CI 1.130–1.481) and stroke (aHR, 1.333; 95% CI 1.093–1.628), which were predominant among those aged 70 years or below. High hsCRP significantly mediated 13.4% of the association between the TyG index and cardiovascular disease, while TyG simultaneously mediated 7.9% of the association between hsCRP and cardiovascular risk.

Conclusions

The findings highlight the coexposure effects and mutual mediation between the TyG index and hsCRP on cardiovascular diseases. Joint assessments of the TyG index and hsCRP should be underlined for the residual risk stratification and primary prevention of cardiovascular diseases, especially for middle-aged adults.

Available only for authorised users

Sacco RL, Roth GA, Reddy KS, Arnett DK, Bonita R, Gaziano TA, Heidenreich PA, Huffman MD, Mayosi BM, Mendis S, et al. The heart of 25 by 25: achieving the goal of reducing global and regional premature deaths from cardiovascular diseases and stroke: a modeling study from the American heart association and world heart federation. Circulation. 2016;133(23):e674-690.PubMedCrossRef

Liu S, Li Y, Zeng X, Wang H, Yin P, Wang L, Liu Y, Liu J, Qi J, Ran S, et al. Burden of cardiovascular diseases in China, 1990–2016: findings from the 2016 global burden of disease study. JAMA Cardiol. 2019;4(4):342–52.PubMedPubMedCentralCrossRef

D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the framingham heart study. Circulation. 2008;117(6):743–53.PubMedCrossRef

Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, Wilson PW. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290(7):891–7.PubMedCrossRef

Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290(7):898–904.PubMedCrossRef

Smith SC Jr. Current and future directions of cardiovascular risk prediction. Am J Cardiol. 2006;97(2):28–32.CrossRef

Magnussen C, Ojeda FM, Leong DP, Alegre-Diaz J, Amouyel P, Aviles-Santa L, De Bacquer D, Ballantyne CM, Bernabé-Ortiz A, Bobak M, et al. Global effect of modifiable risk factors on cardiovascular disease and mortality. N Engl J Med. 2023;389(14):1273–85.PubMedPubMedCentralCrossRef

Fox CS, Coady S, Sorlie PD, D’Agostino RB Sr, Pencina MJ, Vasan RS, Meigs JB, Levy D, Savage PJ. Increasing cardiovascular disease burden due to diabetes mellitus: the framingham heart study. Circulation. 2007;115(12):1544–50.PubMedCrossRef

Schmiegelow MD, Hedlin H, Stefanick ML, Mackey RH, Allison M, Martin LW, Robinson JG, Hlatky MA. Insulin resistance and risk of cardiovascular disease in postmenopausal women: a cohort study from the women’s health initiative. Circ Cardiovasc Qual Outcomes. 2015;8(3):309–16.PubMedCrossRef

10.

Hill MA, Yang Y, Zhang L, Sun Z, Jia G, Parrish AR, Sowers JR. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. 2021;119:154766.PubMedCrossRef

11.

Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299–304.PubMedCrossRef

12.

Tahapary DL, Pratisthita LB, Fitri NA, Marcella C, Wafa S, Kurniawan F, Rizka A, Tarigan TJE, Harbuwono DS, Purnamasari D, et al. Challenges in the diagnosis of insulin resistance: focusing on the role of HOMA-IR and tryglyceride/glucose index. Diabetes Metab Syndr. 2022;16(8):102581.PubMedCrossRef

13.

Tao LC, Xu JN, Wang TT, Hua F, Li JJ. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol. 2022;21(1):68.PubMedPubMedCentralCrossRef

14.

Jin JL, Cao YX, Wu LG, You XD, Guo YL, Wu NQ, Zhu CG, Gao Y, Dong QT, Zhang HW, et al. Triglyceride glucose index for predicting cardiovascular outcomes in patients with coronary artery disease. J Thorac Dis. 2018;10(11):6137–46.PubMedPubMedCentralCrossRef

15.

Won KB, Park EJ, Han D, Lee JH, Choi SY, Chun EJ, Park SH, Han HW, Sung J, Jung HO, et al. Triglyceride glucose index is an independent predictor for the progression of coronary artery calcification in the absence of heavy coronary artery calcification at baseline. Cardiovasc Diabetol. 2020;19(1):34.PubMedPubMedCentralCrossRef

16.

Wu Z, Wang J, Li Z, Han Z, Miao X, Liu X, Li X, Wang W, Guo X, Tao L. Triglyceride glucose index and carotid atherosclerosis incidence in the Chinese population: a prospective cohort study. Nutr Metab Cardiovasc Dis. 2021;31(7):2042–50.PubMedCrossRef

17.

Wu Z, Zhou D, Liu Y, Li Z, Wang J, Han Z, Miao X, Liu X, Li X, Wang W, et al. Association of TyG index and TG/HDL-C ratio with arterial stiffness progression in a non-normotensive population. Cardiovasc Diabetol. 2021;20(1):134.PubMedPubMedCentralCrossRef

18.

Fritz J, Brozek W, Concin H, Nagel G, Kerschbaum J, Lhotta K, Ulmer H, Zitt E. The association of excess body weight with risk of ESKD is mediated through insulin resistance, hypertension, and hyperuricemia. J Am Soc Nephrol. 2022;33(7):1377–89.PubMedPubMedCentralCrossRef

19.

Wu Z, Yu S, Zhang H, Guo Z, Zheng Y, Xu Z, Li Z, Liu X, Li X, Chen S, et al. Combined evaluation of arterial stiffness, glycemic control and hypertension for macrovascular complications in type 2 diabetes. Cardiovasc Diabetol. 2022;21(1):262.PubMedPubMedCentralCrossRef

20.

Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet. 2023;401(10384):1293–301.PubMedCrossRef

21.

Lawler PR, Bhatt DL, Godoy LC, Lüscher TF, Bonow RO, Verma S, Ridker PM. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. 2021;42(1):113–31.PubMedCrossRef

22.

Lan Y, Chen G, Wu D, Ding X, Huang Z, Wang X, Balmer L, Li X, Song M, Wang W, et al. Temporal relationship between atherogenic dyslipidemia and inflammation and their joint cumulative effect on type 2 diabetes onset: a longitudinal cohort study. BMC Med. 2023;21(1):31.PubMedPubMedCentralCrossRef

23.

Feng G, Yang M, Xu L, Liu Y, Yu J, Zang Y, Shen S, Zheng X. Combined effects of high sensitivity C-reactive protein and triglyceride-glucose index on risk of cardiovascular disease among middle-aged and older Chinese: evidence from the China health and retirement longitudinal study. Nutr Metab Cardiovasc Dis. 2023;33(6):1245–53.PubMedCrossRef

24.

Cui C, Liu L, Zhang T, Fang L, Mo Z, Qi Y, Zheng J, Wang Z, Xu H, Yan H, et al. Triglyceride-glucose index, renal function and cardiovascular disease: a national cohort study. Cardiovasc Diabetol. 2023;22(1):325.PubMedPubMedCentralCrossRef

25.

Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219–46.PubMedCrossRef

26.

Bertoni AG, Burke GL, Owusu JA, Carnethon MR, Vaidya D, Barr RG, Jenny NS, Ouyang P, Rotter JI. Inflammation and the incidence of type 2 diabetes: the multi-ethnic study of atherosclerosis (MESA). Diabetes Care. 2010;33(4):804–10.PubMedPubMedCentralCrossRef

27.

Zhao Y, Hu Y, Smith JP, Strauss J, Yang G. Cohort profile: the China health and retirement longitudinal study (CHARLS). Int J Epidemiol. 2014;43(1):61–8.PubMedCrossRef

28.

Wu Z, Zhang H, Miao X, Li H, Pan H, Zhou D, Liu Y, Li Z, Wang J, Liu X, et al. High-intensity physical activity is not associated with better cognition in the elder: evidence from the China health and retirement longitudinal study. Alzheimers Res Ther. 2021;13(1):182.PubMedPubMedCentralCrossRef

29.

Alizargar J, Bai CH, Hsieh NC, Wu SV. Use of the triglyceride-glucose index (TyG) in cardiovascular disease patients. Cardiovasc Diabetol. 2020;19(1):8.PubMedPubMedCentralCrossRef

30.

Li H, Zheng D, Li Z, Wu Z, Feng W, Cao X, Wang J, Gao Q, Li X, Wang W, et al. Association of depressive symptoms with incident cardiovascular diseases in middle-aged and older Chinese adults. JAMA Netw Open. 2019;2(12):e1916591.PubMedPubMedCentralCrossRef

31.

Xie W, Zheng F, Yan L, Zhong B. Cognitive decline before and after incident coronary events. J Am Coll Cardiol. 2019;73(24):3041–50.PubMedCrossRef

32.

He W, Li Q, Yang M, Jiao J, Ma X, Zhou Y, Song A, Heymsfield SB, Zhang S, Zhu S. Lower BMI cutoffs to define overweight and obesity in China. Obesity. 2015;23(3):684–91.PubMedCrossRef

33.

Lenfant C, Chobanian AV, Jones DW, Roccella EJ. Seventh report of the joint national committee on the prevention, detection, evaluation, and treatment of high blood pressure (JNC 7): resetting the hypertension sails. Hypertension. 2003;41(6):1178–9.PubMedCrossRef

34.

Standards of Medical Care in Diabetes-2020 Abridged for Primary Care Providers. Clin Diabetes 2020, 38(1):10–38.

35.

Möhlenkamp S, Lehmann N, Moebus S, Schmermund A, Dragano N, Stang A, Siegrist J, Mann K, Jöckel K-H, Erbel R. Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. J Am Coll Cardiol. 2011;57(13):1455–64.PubMedCrossRef

36.

Wu Z, Jiang Y, Li P, Wang Y, Zhang H, Li Z, Li X, Tao L, Gao B, Guo X. Association of impaired sensitivity to thyroid hormones with hyperuricemia through obesity in the euthyroid population. J Transl Med. 2023;21(1):436.PubMedPubMedCentralCrossRef

37.

Barzegar N, Tohidi M, Hasheminia M, Azizi F, Hadaegh F. The impact of triglyceride-glucose index on incident cardiovascular events during 16 years of follow-up: Tehran lipid and glucose study. Cardiovasc Diabetol. 2020;19(1):155.PubMedPubMedCentralCrossRef

38.

Tian X, Zuo Y, Chen S, Liu Q, Tao B, Wu S, Wang A. Triglyceride-glucose index is associated with the risk of myocardial infarction: an 11-year prospective study in the Kailuan cohort. Cardiovasc Diabetol. 2021;20(1):19.PubMedPubMedCentralCrossRef

39.

Park B, Lee YJ, Lee HS, Jung DH. The triglyceride-glucose index predicts ischemic heart disease risk in Koreans: a prospective study using national health insurance service data. Cardiovasc Diabetol. 2020;19(1):210.PubMedPubMedCentralCrossRef

40.

Gao JW, Hao QY, Gao M, Zhang K, Li XZ, Wang JF, Vuitton DA, Zhang SL, Liu PM. Triglyceride-glucose index in the development of peripheral artery disease: findings from the atherosclerosis risk in communities (ARIC) study. Cardiovasc Diabetol. 2021;20(1):126.PubMedPubMedCentralCrossRef

41.

Sánchez-Íñigo L, Navarro-González D, Fernández-Montero A, Pastrana-Delgado J, Martínez JA. The TyG index may predict the development of cardiovascular events. Eur J Clin Invest. 2016;46(2):189–97.PubMedCrossRef

42.

Hong S, Han K, Park CY. The triglyceride glucose index is a simple and low-cost marker associated with atherosclerotic cardiovascular disease: a population-based study. BMC Med. 2020;18(1):361.PubMedPubMedCentralCrossRef

43.

Li H, Zuo Y, Qian F, Chen S, Tian X, Wang P, Li X, Guo X, Wu S, Wang A. Triglyceride-glucose index variability and incident cardiovascular disease: a prospective cohort study. Cardiovasc Diabetol. 2022;21(1):105.PubMedPubMedCentralCrossRef

44.

Xu X, Huang R, Lin Y, Guo Y, Xiong Z, Zhong X, Ye X, Li M, Zhuang X, Liao X. High triglyceride-glucose index in young adulthood is associated with incident cardiovascular disease and mortality in later life: insight from the CARDIA study. Cardiovasc Diabetol. 2022;21(1):155.PubMedPubMedCentralCrossRef

45.

Huang Z, Ding X, Yue Q, Wang X, Chen Z, Cai Z, Li W, Cai Z, Chen G, Lan Y, et al. Triglyceride-glucose index trajectory and stroke incidence in patients with hypertension: a prospective cohort study. Cardiovasc Diabetol. 2022;21(1):141.PubMedPubMedCentralCrossRef

46.

Yan Y, Wang D, Sun Y, Ma Q, Wang K, Liao Y, Chen C, Jia H, Chu C, Zheng W, et al. Triglyceride-glucose index trajectory and arterial stiffness: results from Hanzhong adolescent hypertension cohort study. Cardiovasc Diabetol. 2022;21(1):33.PubMedPubMedCentralCrossRef

47.

Park B, Lee HS, Lee YJ. Triglyceride glucose (TyG) index as a predictor of incident type 2 diabetes among nonobese adults: a 12-year longitudinal study of the Korean Genome and Epidemiology Study cohort. Transl Res. 2021;228:42–51.PubMedCrossRef

48.

Zheng R, Mao Y. Triglyceride and glucose (TyG) index as a predictor of incident hypertension: a 9-year longitudinal population-based study. Lipids Health Dis. 2017;16(1):175.PubMedPubMedCentralCrossRef

49.

Che B, Zhong C, Zhang R, Pu L, Zhao T, Zhang Y, Han L. Triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio as potential cardiovascular disease risk factors: an analysis of UK biobank data. Cardiovasc Diabetol. 2023;22(1):34.PubMedPubMedCentralCrossRef

50.

Rivière B, Jaussent A, Macioce V, Faure S, Builles N, Lefebvre P, Géraud P, Picot MC, Rebuffat S, Renard E, et al. The triglycerides and glucose (TyG) index: a new marker associated with nonalcoholic steatohepatitis (NASH) in obese patients. Diabetes Metab. 2022;48(4):101345.PubMedCrossRef

51.

Yuan Y, Chen S, Lin C, Huang X, Lin S, Huang F, Zhu P. Association of triglyceride-glucose index trajectory and frailty in urban older residents: evidence from the 10-year follow-up in a cohort study. Cardiovasc Diabetol. 2023;22(1):264.PubMedPubMedCentralCrossRef

52.

Amouzegar A, Honarvar M, Masoumi S, Tohidi M, Mehran L, Azizi F. Sex-specific trajectories of insulin resistance markers and reduced renal function during 18 years of follow-up: TLGS. J Clin Endocrinol Metab. 2023;108(6):e230–9.PubMedCrossRef

53.

Yousuf O, Mohanty BD, Martin SS, Joshi PH, Blaha MJ, Nasir K, Blumenthal RS, Budoff MJ. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013;62(5):397–408.PubMedCrossRef

54.

Kaptoge S, Di Angelantonio E, Lowe G, Pepys M, Thompson S, Collins R, Danesh J. Emerging risk factors collaboration C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132–40.PubMedCrossRef

55.

Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the US preventive services task force. Ann Intern Med. 2009;151(7):483–95.PubMedCrossRef

56.

Dong Y, Wang X, Zhang L, Chen Z, Zheng C, Wang J, Kang Y, Shao L, Tian Y, Wang Z. High-sensitivity C reactive protein and risk of cardiovascular disease in China-CVD study. J Epidemiol Community Health. 2019;73(2):188–92.PubMedCrossRef

57.

McGillicuddy FC, de la Llera MM, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, Rothblat GH, Reilly MP. Inflammation impairs reverse cholesterol transport in vivo. Circulation. 2009;119(8):1135–45.PubMedPubMedCentralCrossRef

58.

Ruan GT, Xie HL, Zhang HY, Liu CA, Ge YZ, Zhang Q, Wang ZW, Zhang X, Tang M, Song MM, et al. A novel inflammation and insulin resistance related indicator to predict the survival of patients with cancer. Front Endocrinol. 2022;13:905266.CrossRef

59.

Haffner SM. Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes Res Clin Pract. 2003;61(Suppl 1):S9-s18.PubMedCrossRef

60.

Ruan GT, Xie HL, Gong YZ, Ge YZ, Zhang Q, Wang ZW, Zhang X, Zhang HY, Tang M, Song MM, et al. Prognostic importance of systemic inflammation and insulin resistance in patients with cancer: a prospective multicenter study. BMC Cancer. 2022;22(1):700.PubMedPubMedCentralCrossRef

61.

Zhang N, Xiang Y, Zhao Y, Ji X, Sang S, Shao S, Ma X, Wang G, Lv M, Xue F, et al. Association of triglyceride-glucose index and high-sensitivity C-reactive protein with asymptomatic intracranial arterial stenosis: a cross-sectional study. Nutr Metab Cardiovasc Dis. 2021;31(11):3103–10.PubMedCrossRef

62.

Lan Y, Wu D, Cai Z, Xu Y, Ding X, Wu W, Lan S, Chen L, Guo Z, Balmer L, et al. Supra-additive effect of chronic inflammation and atherogenic dyslipidemia on developing type 2 diabetes among young adults: a prospective cohort study. Cardiovasc Diabetol. 2023;22(1):181.PubMedPubMedCentralCrossRef

63.

Mirzababaei A, Abaj F, Khosravinia D, Ghorbani M, Valisoltani N, Clark CCT, Radmehr M, Mirzaei K. The mediatory effect of inflammatory markers on the association between a body shape index and body roundness index with cardiometabolic risk factor in overweight and obese women: a cross-sectional study. Front Nutr. 2023;10:1178829.PubMedPubMedCentralCrossRef

64.

Li T, Wang P, Wang X, Liu Z, Zhang Z, Zhang Y, Wang Z, Feng Y, Wang Q, Guo X, et al. Inflammation and insulin resistance in diabetic chronic coronary syndrome patients. Nutrients. 2023. https://doi.org/10.3390/nu15122808.CrossRefPubMedPubMedCentral

65.

Aroor AR, McKarns S, Demarco VG, Jia G, Sowers JR. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism. 2013;62(11):1543–52.PubMedCrossRef

66.

Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):122.PubMedPubMedCentralCrossRef

67.

Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM. 2003;96(11):793–807.PubMedCrossRef

68.

Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017;127(1):1–4.PubMedPubMedCentralCrossRef

Title: Joint association of TyG index and high sensitivity C-reactive protein with cardiovascular disease: a national cohort study
Authors: Cancan Cui
Lin Liu
Yitian Qi
Ning Han
Haikun Xu
Zhijia Wang
Xinyun Shang
Tianjiao Han
Yining Zha
Xin Wei
Zhiyuan Wu
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Insulins
Insulins
Coronary Heart Disease
Published in: Cardiovascular Diabetology / Issue 1/2024
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/s12933-024-02244-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Association of triglyceride glucose index and triglyceride glucose-body mass index with sudden cardiac arrest in the general population

Protective effects of imeglimin on the development of atherosclerosis in ApoE KO mice treated with STZ

Evidence that tirzepatide protects against diabetes-related cardiac damages

Correlation between triglyceride glucose index and collateral circulation formation in patients with chronic total occlusion of coronary arteries in different glucose metabolic states

Characterizing the metabolic divide: distinctive metabolites differentiating CAD-T2DM from CAD patients

Association of the triglyceride glucose-body mass index with the extent of coronary artery disease in patients with acute coronary syndromes

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials